Olutasidenib (NCT06566742)

Name: Olutasidenib trial for Myelodysplastic Syndromes (NCT06566742)
Uploaded: 2026-10-31T15:13:10.078Z
Duration: 1 min 12 s
Description: Olutasidenib trial for Myelodysplastic Syndromes (NCT06566742). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06566742.

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.: a one-minute explainerNCT065667421 min

Olutasidenib trial for Myelodysplastic Syndromes (NCT06566742). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with an IDH1 mutation and lower-risk MDS, CMML or clonal cytopenia of undetermined significance. The last condition means unexplained low blood counts with a blood-cell mutation, without a diagnosed myeloid cancer.

The idea: oral olutasidenib blocks mutant IDH1, aiming to let abnormal cells mature. Participants take it twice daily in 28-day cycles. Researchers assess blood-count responses, safety and disease changes. Blood tests and bone-marrow sampling are planned; treatment duration differs by diagnosis.

This phase 2 study plans 15 patients. MD Anderson sponsors it; Miami and Houston are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.